Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | MMP7 | P09237 | 1/20 | 0.56 |
| ▸ | MMP14 | P50281 | 4/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | MMP1 | P03956 | 4/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | MMP9 | P14780 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3940017 | 0.93 | CYP3A4 (0.72) | MMP13CYP3A4MMP7MMP14ADAMTS4 | |
| SCHEMBL13923643 | 0.93 | CYP3A4 (0.72) | MMP13CYP3A4MMP7MMP14ADAMTS4 | |
| SCHEMBL13923653 | 0.91 | MMP13 (0.52) | MMP13CYP3A4MMP7MMP14ADAMTS4 | |
| SCHEMBL13923646 | 0.90 | MMP13 (0.57) | MMP13CYP3A4MMP7MMP14ADAMTS4 | |
| SCHEMBL13923649 | 0.88 | CYP3A4 (0.80) | MMP13CYP3A4MMP7MMP14ADAMTS4 | |
| SCHEMBL5884462 | 0.85 | MMP7 (0.61) | MMP13CYP3A4MMP7MMP14ADAMTS4 | |
| SCHEMBL5883498 | 0.85 | MMP7 (0.61) | MMP13CYP3A4MMP7MMP14ADAMTS4 | |
| SCHEMBL8304365 | 0.84 | ADAMTS4 (0.58) | MMP13CYP3A4MMP7MMP14ADAMTS4 | |
| SCHEMBL13923650 | 0.84 | MMP13 (0.61) | MMP13CYP3A4MMP7MMP14ADAMTS4 | |
| SCHEMBL8304549 | 0.82 | MMP13 (0.61) | MMP13CYP3A4MMP7MMP14ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | MMP26, MMP9, MMP3 | MMP13 8/4885CYP3A4 466/4885MMP7 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.